Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Paxil CR returns

Executive Summary

GlaxoSmithKline resumes shipment of Paxil CR, four months after manufacturing problems led to FDA's seizure of the product at distribution and production facilities (1"The Pink Sheet" March 21, 2005, p. 15). Sales reps will offer 30-day free trial vouchers to support reintroduction; Paxil CR will be a "priority" for sales force, GSK says. Resupply of Avandamet, which also was seized by FDA, is projected to begin by mid-July...

You may also be interested in...

FDA Expects Consent Decree For GSK As Follow-Up To Seizure Action

FDA expects to enter into a consent decree with GlaxoSmithKline to resolve manufacturing violations at its Cidra, Puerto Rico facility following the seizure of Paxil CR and Avandamet

Pink Sheet Podcast: Woodcock To Be Acting US FDA Chief, Key Staff Depart, Political Donations Shift

Pink Sheet reporters and editor discuss President-Elect Joe Biden’s decision to name the CDER director as acting FDA commissioner and other staffing changes, as well as changes to industry trade groups’ political donations.

Liquid Biopsy Company Delfi Diagnostics Raised $100M For New Class of Early Cancer Detection Test

Delfi Diagnostics will use the new funds to expand its team of cancer researchers and machine-learning experts to validate its novel approach for early cancer detection through multiple prospective clinical trials. 





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts